Literature DB >> 23398531

Modulating cocaine vaccine potency through hapten fluorination.

Xiaoqing Cai1, Kyoji Tsuchikama, Kim D Janda.   

Abstract

Cocaine addiction is a long-lasting relapsing illness characterized by cycles of abuse, abstinence, and reinstatement, and antibody-based therapies could be a powerful therapeutic approach. Herein, we explored the possibility of using halogenated cocaine haptens to enhance the immunological properties of anti-cocaine vaccines. Three fluorine-containing cocaine haptens (GNF, GNCF and GN5F) and one chlorine-containing cocaine hapten (GNCl) were designed and synthesized, based upon the chemical scaffold of the only hapten that has reached clinical trials, succinyl norcocaine (SNC). Hapten GNF was found to retain potent cocaine affinity, and also elicit antibodies in a higher concentration than the parent structure SNC. Our data suggests that not only could strategic hapten fluorination be useful for improving upon the current cocaine vaccine undergoing clinical trials, but it may also be a valuable new approach, with application to any of the vaccines being developed for the treatment of drugs of abuse.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23398531      PMCID: PMC3637684          DOI: 10.1021/ja400356g

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  24 in total

Review 1.  The polar hydrophobicity of fluorinated compounds.

Authors:  Justin C Biffinger; Hong Woo Kim; Stephen G DiMagno
Journal:  Chembiochem       Date:  2004-05-03       Impact factor: 3.164

2.  Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen.

Authors:  Fan Yang; Xiu-Jing Zheng; Chang-Xin Huo; Yue Wang; Ye Zhang; Xin-Shan Ye
Journal:  ACS Chem Biol       Date:  2011-01-07       Impact factor: 5.100

3.  Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.

Authors:  Anja Hoffmann-Röder; Anton Kaiser; Sarah Wagner; Nikola Gaidzik; Danuta Kowalczyk; Ulrika Westerlind; Bastian Gerlitzki; Edgar Schmitt; Horst Kunz
Journal:  Angew Chem Int Ed Engl       Date:  2010-11-02       Impact factor: 15.336

4.  Human therapeutic cocaine vaccine: safety and immunogenicity.

Authors:  Thomas R Kosten; Marc Rosen; Julian Bond; Michael Settles; John St Clair Roberts; John Shields; Lindsay Jack; Barbara Fox
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

5.  Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay.

Authors:  R Müller
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  Fluorinated glycosyl amino acids for mucin-like glycopeptide antigen analogues.

Authors:  Sarah Wagner; Christian Mersch; Anja Hoffmann-Röder
Journal:  Chemistry       Date:  2010-06-25       Impact factor: 5.236

7.  Synthesis and biological activity of cocaine analogs I: N-alkylated norcocaine derivatives.

Authors:  E S Lazer; N D Aggarwal; G J Hite; K A Nieforth; R T Kelleher; R D Spealman; C R Schuster; W Wolverton
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

8.  Impact of distinct chemical structures for the development of a methamphetamine vaccine.

Authors:  Amira Y Moreno; Alexander V Mayorov; Kim D Janda
Journal:  J Am Chem Soc       Date:  2011-04-07       Impact factor: 15.419

9.  Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans.

Authors:  Margaret Haney; Erik W Gunderson; Huiping Jiang; Eric D Collins; Richard W Foltin
Journal:  Biol Psychiatry       Date:  2010-01-01       Impact factor: 13.382

10.  Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.

Authors:  Bridget A Martell; Frank M Orson; James Poling; Ellen Mitchell; Roger D Rossen; Tracie Gardner; Thomas R Kosten
Journal:  Arch Gen Psychiatry       Date:  2009-10
View more
  16 in total

Review 1.  Recent advances in the molecular design of synthetic vaccines.

Authors:  Lyn H Jones
Journal:  Nat Chem       Date:  2015-12       Impact factor: 24.427

2.  Investigations into the efficacy of multi-component cocaine vaccines.

Authors:  Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-12-20       Impact factor: 2.823

3.  Methamphetamine Vaccines: Improvement through Hapten Design.

Authors:  Karen C Collins; Joel E Schlosburg; Paul T Bremer; Kim D Janda
Journal:  J Med Chem       Date:  2016-04-19       Impact factor: 7.446

Review 4.  Adjuvants for vaccines to drugs of abuse and addiction.

Authors:  Carl R Alving; Gary R Matyas; Oscar Torres; Rashmi Jalah; Zoltan Beck
Journal:  Vaccine       Date:  2014-08-08       Impact factor: 3.641

Review 5.  Vaccines against drugs of abuse: where are we now?

Authors:  Berma Kinsey
Journal:  Ther Adv Vaccines       Date:  2014-07

Review 6.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

7.  Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.

Authors:  Cody J Wenthur; Xiaoqing Cai; Beverly A Ellis; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-07-05       Impact factor: 2.823

8.  Enhancement of a Heroin Vaccine through Hapten Deuteration.

Authors:  Tyson F Belz; Paul T Bremer; Bin Zhou; Beverly Ellis; Lisa M Eubanks; Kim D Janda
Journal:  J Am Chem Soc       Date:  2020-07-27       Impact factor: 15.419

9.  Hapten optimization for cocaine vaccine with improved cocaine recognition.

Authors:  Muthu Ramakrishnan; Berma M Kinsey; Rana A Singh; Thomas R Kosten; Frank M Orson
Journal:  Chem Biol Drug Des       Date:  2014-07-29       Impact factor: 2.817

10.  Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

Authors:  M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.